Convulsive Status Epilepticus in Decompensated Cirrhosis
52-year-old man with alcohol-related cirrhosis (MELD 24) has a 3-minute generalized tonic-clonic seizure in the emergency department. He receives IV lorazepam 10 mg and the convulsion stops, but he remains somnolent. Labs: sodium 128, ammonia 110, creatinine 1.4, albumin 2.1, INR 1.8, platelets 70. He takes lactulose and spironolactone; no prior seizures. EEG shows diffuse slowing and intermittent generalized sharp waves without electrographic seizures. The team wonders whether to load a second-line antiseizure medication, which one, and whether this is an acute provoked seizure or new epilepsy.
1. Which second-line antiseizure medication would you choose after benzodiazepines, and how does his liver disease change dosing and monitoring?
Read the worked answer
I would choose levetiracetam 60 mg/kg IV (maximum 4,500 mg) as the second-line agent. It is renally cleared, has minimal hepatic metabolism, and does not require protein-binding adjustment. His creatinine is 1.4, so the maintenance dose should be reduced after the load, for example 500–1,000 mg every 12 hours depending on calculated clearance, with attention to sedation and agitation.
I would avoid valproate because of cirrhosis, coagulopathy, thrombocytopenia, and hyperammonemia. Phenytoin is problematic because hypoalbuminemia and renal impairment make free levels unpredictable, and IV loading carries cardiac risk. Lacosamide is an alternative but has partial hepatic metabolism and can prolong the PR interval. Monitoring should include respiratory status, mental status, ammonia, and continuous EEG if he does not recover as expected.
2. Does the EEG finding change your decision to continue long-term therapy?
Read the worked answer
Not by itself. The EEG shows diffuse slowing and intermittent generalized sharp waves but no electrographic seizures. In a patient with hyponatremia, hyperammonemia, and decompensated cirrhosis, this is most consistent with a metabolically provoked seizure and encephalopathy rather than newly diagnosed epilepsy. Interictal sharp waves can reflect acute metabolic dysfunction and do not prove an enduring epileptogenic substrate.
I would continue levetiracetam short term while correcting sodium and ammonia and treating withdrawal or infection, then reassess. If he has a recurrent unprovoked seizure, a structural lesion on MRI, or persistent epileptiform discharges after metabolic correction, long-term therapy is more defensible. If he remains seizure-free and the EEG normalizes, I would consider tapering after about 1–2 weeks rather than committing him indefinitely.
3. If he has another seizure 6 hours later despite levetiracetam, what is the next step?
Read the worked answer
This is recurrent status epilepticus and requires a structured escalation. I would give another benzodiazepine dose, secure the airway, and start a continuous EEG. Because he has already received lorazepam and is on levetiracetam, I would add a second agent such as fosphenytoin with free-level monitoring, or lacosamide if phenytoin is unsuitable, and consider a midazolam infusion if seizures persist.
In cirrhosis, I would avoid propofol-based prolonged sedation if hemodynamics are marginal and would monitor for accumulation of benzodiazepines and midazolam. I would also search for a precipitant: infection, gastrointestinal bleeding, medication nonadherence, alcohol withdrawal, or worsening hyponatremia. The goal is to stop electrographic seizures and treat the cause, not simply to keep adding maintenance drugs.